Art

J-GLOBAL ID：201402293444962339   Reference number：14A0907205

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

中等度催吐性化学療法後の化学療法誘発悪心および嘔吐の予防のためのネツピタントとパロノセトロンの用量固定併用NEPAの有効性と安全性を評価するランダム化第III相試験

Author (13)： AAPRO M. (Univ. California San Francisco, San Francisco, USA) ,  RUGO H. (Univ. California San Francisco, San Francisco, USA) ,  ROSSI G. (Helsinn Healthcare, Lugano, CHE) ,  RIZZI G. (Helsinn Healthcare, Lugano, CHE) ,  BORRONI M. E. (Helsinn Healthcare, Lugano, CHE) ,  BONDARENKO I. (Dnepropetrovsk Medical Acad., Dnepropetrovsk, UKR) ,  SAROSIEK T. (Nzoz Magodent, Warsaw, POL) ,  OPREAN C. (Oncomed SRL, Timisoara, ROM) ,  CARDONA-HUERTA S. (Universidad Autonoma de Nuevo Leon, Monterrey, MEX) ,  LORUSSO V. (National Cancer Inst. Glovanni Paolo II, Bari, ITA) ,  KARTHAUS M. (Staedt. Klinikum Neuperlach and Harlaching, Muenchen, DEU) ,  SCHWARTZBERG L. (West Clinic, Memphis) ,  GRUNBERG S. (Fletcher Allen Health Care, Burlington, USA)
Material： Annals of Oncology  (Ann Oncol)
Volume： 25  Issue： 7  Page： 1328-1333  Publication year： Jul. 2014 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： NEPA ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A0907205&from=J-GLOBAL&jstjournalNo=W0107A") }}

JST classification (2)： Clinical application of drugs acting on digestive system  (GW09020B) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (3)： Netupitant ,  Dexamethasone ,  Palonosetron

Reference (13)：

• Frame DG. Best practice management of CINV in oncology patients: I. physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol 2010; 8(1): 5-9.
• Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011; 22(1): 30-38.
• Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21(5): 232-243.
• Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23(12): 2822-2830.
• Aapro M, Molassiotis A, Dicato M et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012; 23(8): 1986-1992.

Terms in the title (13)： 化学療法 ,  誘発 ,  悪心 ,  嘔吐 ,  予防 ,  ネツピタント ,  パロノセトロン ,  用量 ,  併用 ,  有効性 ,  安全性 ,  評価 ,  第III相試験